Navigation Links
Regado Biosciences, Inc. Announces Pricing of Initial Public Offering

BASKING RIDGE, N.J., Aug. 21, 2013 /PRNewswire/ -- Regado Biosciences, Inc., today announced the pricing of its initial public offering of 10,750,000 shares of its common stock at a price to the public of $4.00 per share, before underwriting discounts.  All of the common stock is being offered by Regado Biosciences.  In addition, Regado Biosciences has granted the underwriters a 30-day option to purchase up to an additional 925,000 shares of common stock at the initial public offering price to cover over-allotments, if any, at the initial public offering price.  The shares are scheduled to begin trading on the NASDAQ Capital Market on August 22, 2013 under the ticker symbol "RGDO."  The offering is expected to close on August 27, 2013, subject to customary closing conditions.

Cowen and Company, LLC and BMO Capital Markets Corp. are acting as joint book-running managers for the offering.  Canaccord Genuity Inc., Needham & Company, LLC, and Wedbush PacGrow Life Sciences are acting as co-managers.  The offering will be made only by means of a prospectus.  Copies of the final prospectus related to the offering may be obtained, when available, from Cowen and Company, LLC, c/o Broadridge Financial Services, 1155 Long Island Avenue, Edgewood, NY,11717, Attn: Prospectus Department, Phone (631) 274-2806 / Fax (631) 254-7140; or from BMO Capital Markets Corp., Attention: Equity Syndicate Department, 3 Times Square, New York, NY 10036, Telephone: (800) 414-3627, Email:

A registration statement relating to these securities was declared effective by the Securities and Exchange Commission on August 21, 2013.  This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

Regado Biosciences, Inc. is a biopharmaceutical company focused on the discovery and development of novel, first-in-class, actively controllable antithrombotic drug systems for acute and sub-acute cardiovascular indications. Regado is pioneering the discovery and development of two-component drug systems consisting of a therapeutic aptamer and its specific active control agent. The company's lead product candidate, REG1, is an actively controllable anticoagulant targeting coagulation Factor IXa for use in patients with a wide variety of acute coronary syndromes, or ACS, undergoing a percutaneous coronary intervention, or PCI, a hospital-based procedure used to mechanically open or widen obstructed coronary arteries. The actively controllable product candidates have the potential to improve outcomes, enhance the patient experience and reduce overall treatment costs.  More information can be found at

Tiberend Strategic Advisors, Inc.
Joshua Drumm, Ph.D./Andrew Mielach; (212) 375-2664; (212) 375-2694

SOURCE Regado Biosciences, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Regado Biosciences, Inc. to Present at the Oppenheimer 23rd Annual Healthcare Conference in New York, NY
2. Regado Biosciences, Inc. to Present at the UBS Global Life Sciences Conference 2012 in New York, NY
3. Regado Biosciences, Inc. to Present at the Canaccord Genuity 32nd Annual Growth Conference in Boston, MA
4. Regado Biosciences, Inc. to Present at the 2012 Wedbush PacGrow Life Sciences Conference in New York, NY
5. Pressure BioSciences, Inc. to Present at the Marcum MicroCap Conference
6. Bernstein Liebhard LLP Announces That A Class Action Has Been Filed Against Ventrus Biosciences, Inc.
7. Pressure BioSciences, Inc. to Present at the SeeThruEquity Spring Investor Microcap Forum
8. Pressure BioSciences, Inc. to Discuss Third Quarter 2012 Financial Results and Provide Business Update
9. Pressure BioSciences, Inc. Reports 70% Revenue Growth for Second Consecutive Quarter
10. Pressure BioSciences, Inc. to Discuss Second Quarter 2012 Financial Results and Provide Business Update
11. Founded by Enlight Biosciences, KNODE partners with AstraZeneca and Other Partners
Post Your Comments:
(Date:12/1/2015)...  Athletic apparel company Tommie Copper , ... $1.35 million to settle Federal Trade Commission charges ... clothing would relieve severe and chronic pain and ... Tommie Copper,s proposed settlement with ... founder and chairman Thomas Kallish to ...
(Date:12/1/2015)... , 1 de diciembre de 2015 /PRNewswire/ ... para cuchillas de precisión, develó hoy un ... identidad de marca. El nuevo logo destaca ... y la ingeniería de productos con cuchillas ... ...
(Date:12/1/2015)... PUNE, India , December 1, 2015 ... to a new market research report "Nucleic Acid Labeling ... Techniques (PCR, Nick Translation, Random Primer, In Vitro Transcription, ... to 2020", published by MarketsandMarkets, The global market is ... USD 1,271.8 Million in 2015, growing at a CAGR ...
Breaking Medicine Technology:
(Date:12/1/2015)... ... December 01, 2015 , ... Califia Farms , ... that its iconic bottle has won top honors in Beverage World Magazine’s Global Packaging ... also announced that it has been selected as a 2015 U.S.A. Taste Champion in ...
(Date:12/1/2015)... ... 2015 , ... December 1, 2015 -- InstantLabs is adding ... product line of food safety and seafood fraud prevention tools. , The new ... InstantLabs to offer fast, reliable species identification for the four most popular salmon. ...
(Date:12/1/2015)... ... December 01, 2015 , ... ... have been lifted as IMAGE Information Systems launches MED-TAB™ -- the world’s first ... Annual Meeting from November 29 to December 4, 2015. , MED-TAB is ...
(Date:12/1/2015)... ... December 01, 2015 , ... For the millions of ... Hollister Incorporated has launched the VaPro Plus Pocket™ touch free hydrophilic intermittent catheter. ... touch free catheter portfolio,” said Michael Gresavage, Vice President North America. "We designed ...
(Date:12/1/2015)... ... December 01, 2015 , ... McLean, VA., December 1, 2015 ... price per sprint agile development contract to support the National Geospatial-Intelligence Agency's (NGA) ... provides software engineering, infrastructure, as well as operations and sustainment support to the ...
Breaking Medicine News(10 mins):